Publication date: Aug 07, 2024
Vortioxetine has demonstrated safety and efficacy in improving symptoms of major depressive disorder (MDD), including overall functioning in real-world settings. This is the first study in a real-life clinical setting in India to evaluate effectiveness and safety of vortioxetine in patients with MDD. This interventional, open-label study consisted of a 12-week treatment period with flexible doses of vortioxetine (5-20 mg/day) in adult patients (aged 18-65 years) with a confirmed MDD diagnosis. Effectiveness outcomes included change from baseline to week 12 in Patient Health Questionnaire-9 (PHQ-9) and Clinical Global Impression-Severity (CGI-S) scores, along with CGI-Improvement (CGI-I) scores at week 12, using a mixed model for repeated measures. Adverse events (AEs) were recorded for safety outcome assessments. Of 395 patients who received vortioxetine, 42. 3% were women mean age 38. 9 years; 322 patients completed the study. Significant improvement in depressive symptoms was observed in change from baseline to week 12 least squares (LS) mean (SE) PHQ-9 total score (-9. 36 [0. 276]; p
Concepts | Keywords |
---|---|
20mg | antidepressive agents |
9years | effectiveness |
Depressive | Major depressive disorder |
Effectiveness | PHQ-9 |
Vortioxetine | real-life clinical setting |
safety | |
vortioxetine |
Semantics
Type | Source | Name |
---|---|---|
drug | DRUGBANK | Vortioxetine |
disease | MESH | major depressive disorder |